procès daval: le terrible face-à-face
Published 3 years ago • 140K plays • Length 8:13Download video MP4
Download video MP3
Similar videos
-
54:13
treatment options for dlbcl
-
1:29
bispecific bcma-cd3 antibody teclistamab is efficacious and tolerable in r/r mm
-
4:49
course preview: advanced ablation techniques in liver cancer care
-
2:15
real-world outcomes of autosct in patients with wm: a report from lwp ebmt
-
3:34
exciting results for bcma/cd3 bispecific elranatamab (pf-3135) in r/r mm
-
1:24
fighting #dlbcl by attacking the microenviroment | leandro cerchietti, md | ash 2023
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
2:40
lba: karmma-3 results - ide-cel vs standard regimens in triple-class exposed multiple myeloma
-
1:15
personalized medicine for dlbcl
-
41:46
dcvax-l phase 3 trial results
-
8:00
cd3 x cd33 bispecific antibodies redirect donor t-cells against hla loss
-
0:31
can-fite biopharma: developing treatments for liver cancer
-
4:53
new evidence in treating bicuspid tavi patients: insights from bivolut-x registry - pcr ecourse 2020
-
3:27
sorafenib vs placebo in treatment-naïve flt3-itd aml
-
15:41
progress report iii - blanka rebeka bódy
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
4:45
petra langerbeins phd, eha 2019 – results of the phase iii double-blind randomised cll12 trial
-
20:20
regulatory trials in tumors
-
3:30
esc tv at esc congress 2019 - combined effect of lower ldl-c & lower sbp (investigator)